摘要
目的探究索马鲁肽治疗2型糖尿病(T2DM)患者的临床效果。方法选取2019年1月至2021年12月安徽医科大学附属宿州医院收治的T2DM患者160例,采用随机数字表法将其分为观察组和对照组,各80例。对照组口服二甲双胍,观察组在对照组基础上加用索马鲁肽,两组治疗周期均为3个月。比较两组治疗前后体重指数(BMI)、血糖指标[空腹血糖(FBG)、餐后2 h血糖(2hPBG)、糖化血红蛋白(HbAlc)]、血脂指标[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、血清炎症指标[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]水平。比较两组不良总反应发生率。结果治疗后,两组BMI与血糖水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组TG、TC、LDL-C低于治疗前,HDL-C高于治疗前,且观察组TG、TC、LDL-C低于对照组,HDL-C高于对照组(P<0.05)。治疗后,两组炎症因子水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论索马鲁肽治疗T2DM效果更显著,可以有效改善血糖、血脂以及炎症指标,减轻患者体重且无明显不良反应,推荐临床应用。
Objective To explore the clinical effect of Somalutide on patients with type 2 diabetes mellitus(T2DM).Methods A total of 160 patients with T2DM admitted to Suzhou Hospital Affiliated to Anhui Medical University from January 2019 to December 2021 were selected,and they were divided into observation group and control group by random number table method,with 80 cases in each group.The control group was treated with Metformin orally,the observation group was treated with Somarlutide based on the control group.The treatment cycle of the two groups was three months.Body mass index(BMI),blood glucose indexes(fasting blood glucose[FBG],2-hour postprandial blood glucose[2hPBG],glycosylated hemoglobin[HbAlc]),blood lipid indexes(total cholesterol[TC],triglyceride[TG],low-density lipoprotein cholesterol[LDL-C],high-density lipoprotein cholesterol[HDL-C]),and serum inflammatory index(the levels of hypersensitive C-reactive protein[hs-CRP],tumor necrosis factor-α[TNF-α],interleukin-6[IL-6])were compared between the two groups before and after treatment,and the incidence of adverse reactions were compared between the two groups.The incidence of adverse reactions was compared between the two groups.Results After treatment,BMI and blood glucose levels in the two groups were lower than before treatment,and the observation group was lower than the control group,the differences were statistically significant(P<0.05).After treatment,TG,TC and LDL-C in two groups were lower than before treatment,and HDL-C was higher than before treatment.TG,TC and LDL-C in observation group were lower than control group,and HDL-C was higher than control group,the differences were statistically significant(P<0.05).After treatment,the levels of inflammatory factors in the two groups were lower than before treatment and the observation group was lower than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Somalupt
作者
王梦莹
张贺成
王芳
叶启宝
WANG Mengying;ZHANG Hecheng;WANG Fang;YE Qibao(Department of Endocrinology,Suzhou Hospital Affiliated to Anhui Medical University,Anhui Province,Suzhou234000,China;Department of Endocrinology,Binhu District,Hefei First People’s Hospital,Anhui Province,Hefei233000,China)
出处
《中国医药导报》
CAS
2023年第12期86-89,共4页
China Medical Herald
基金
安徽省自然科学基金资助项目(1908085MH267)。
关键词
索马鲁肽
二甲双胍
2型糖尿病
肥胖
血糖
Somaluptide
Metformin
Type 2 diabetes mellitus
Obesity
Blood sugar
